Compare FOSL & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FOSL | VYGR |
|---|---|---|
| Founded | 1984 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.1M | 236.0M |
| IPO Year | N/A | 2015 |
| Metric | FOSL | VYGR |
|---|---|---|
| Price | $5.54 | $3.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $7.00 | ★ $16.50 |
| AVG Volume (30 Days) | ★ 648.4K | 568.4K |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,135,000.00 |
| Revenue This Year | N/A | $34.04 |
| Revenue Next Year | $1.66 | $7.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.86 | $2.65 |
| 52 Week High | $5.49 | $5.55 |
| Indicator | FOSL | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 70.24 | 48.20 |
| Support Level | $3.36 | $3.72 |
| Resistance Level | N/A | $4.30 |
| Average True Range (ATR) | 0.23 | 0.20 |
| MACD | 0.10 | -0.00 |
| Stochastic Oscillator | 97.50 | 50.00 |
Fossil Group Inc is a design, innovation and distribution company in consumer fashion accessories. The products include traditional watches, smartwatches, jewelry, handbags, small leather goods, belts and sunglasses. The reportable segments are comprised of 1) Americas segment includes sales in Canada, Latin America and the United States. 2) Europe segment includes sales in European countries, the Middle East and Africa. 3) Asia segment includes sales in Australia, China, India, Indonesia, Japan, Malaysia, New Zealand, Singapore, South Korea and Thailand. Each reportable operating segment includes sales to wholesale and distributor customers, and sales through Company-owned retail stores and e-commerce activities based on the location of the selling entity.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.